Current concepts of hypercalcemia in sarcoidosis
https://doi.org/10.24884/1609-2201-2025-104-1-44-53
Abstract
Currently, the prevalence of sarcoidosis is rapidly increasing. And there are frequent cases of increased calcium, which in modern clinical realities are not given enough attention. The pathology of calcium metabolism in this disease has a multi-component nature and can not only worsen the patient's condition, but also determine the degree of disease activity. Our article discusses the main links in the pathogenesis of calcium metabolism disorders in sarcoidosis, as well as renal dysfunction that can occur as a result of this pathology. Attention is paid to changes in bone metabolism in patients with sarcoidosis as such (especially against the background of glucocorticoid therapy), and those formed as a result of long-term uncompensated hypercalcemia. An algorithm for examining a patient with hypercalcemia in sarcoidosis is also presented and ways to correct changes in calcium metabolism are outlined.
About the Authors
V. V. Salukhov
S. M. Kirov Military Medical Academy
Russian Federation
Russian Federation
Vladimir V. Salukhov, Dr. of Sci. (Med.), professor, head of the 1st department (advanced therapy for doctors)
6, Akademika Lebedeva, Saint Petersburg, 194044
E. A. Kovalevskaya
S. M. Kirov Military Medical Academy
Russian Federation
Russian Federation
Elena A. Kovalevskaya, Cand. of Sci. (Med.), Senior lecturer of the 1st department (advanced therapy for doctors)
6, Akademika Lebedeva, Saint Petersburg, 194044
Ju. S. Burkova
S. M. Kirov Military Medical Academy
Russian Federation
Russian Federation
Julia S. Burkova, Cand. of Sci. (Med.), Senior lecturer of the 1st department (advanced therapy for doctors)
6, Akademika Lebedeva, Saint Petersburg, 194044
References
1. Lenshin A. V., Ilyin A. V., Ignatyeva E. A., Odireev A. N. Some aspects from the history of sarcoidosis study. Bulletin of Physiology and Pathology of Respiration. 2023;87:138–152. https://doi.org/10.36604/1998-5029-2023-87-138-152. (In Russ.).
2. Clinical guidelines Sarcoidosis. Ministry of Health of the Russian Federation 2022 URL: https://cr.minzdrav.gov.ru/recomend/736_1?ysclid=m4goif012l39397336.8 (date accessed: 09.12.2024). (In Russ.).
3. Vizel A. A., Vizel I. Yu., Shakirova G. R. Evaluation of the efÏcacy and safety of methotrexate in progressive sarcoidosis: a retrospective observational study. Pulmonology. 2020;30(2):213–218. https://doi.org/10.18093/0869-0189-2020-30-2-213-218. (In Russ.).
4. Vizel A. A., Vizel I. Yu. Sarcoidosis: what we know and what we can. Practical Pulmonology. 2018;1:65–68. URL: https://cyberleninka.ru/article/n/sarkoidoz-chto-my-znaem-i-chto-my-mozhem (date of access: 09.12.2024). (In Russ.).
5. Practical Pulmonology / eds by V. V. Salukhov. 2017. 416 p. (In Russ.).
6. Postnikova L. B., Gudim A. L., Boldina M. V., Kubysheva N. I. Clinical phenotypes of patients with sarcoidosis in real clinical practice. Siberian Medical Review. 2022;3:91–99. URL: https://cyberleninka.ru/article/n/klinicheskie-fenotipy-bolnyh-sarkoidozom-v-realnoy-klinicheskoypraktike (date of access: 09.12.2024). (In Russ.).
7. Bargagli E., Prasse A. Sarcoidosis: a review for the internist. Intern. Emerg. Med. 2018;13(3):325–331. https://doi.org/10.1007/s11739-017-1778-6.
8. Baughman R. P., Culver D. A., Judson M. A. A concise review of pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 2011;183(5):573–581. https://doi.org/10.1164/rccm.201006-0865CI.
9. Patterson K. C., Chen E. S. The pathogenesis of pulmonary sarcoidosis and implications for treatment. Chest. 2018;153(6):1432–1442. https:// doi.org/10.1016/j.chest.2017.11.030.
10. Harrel G., Fisher S. Blood chemical changes in Boeck’s sarcoid with particular reference to protein, calcium and phosphatase levels. J. ClinInvest. 1939;18:687–93.
11. Muther R., McCarron D., Bennett W. Renal manifestations of sarcoidosis. Arch. Intern. Med. 1981;141:643–5. https://doi.org/10.1001/ARCHINTE.1981.00340050089019.
12. Conron M., Young C., Beynon H. L. C. Calcium metabolism in sarcoidosis and its clinical implications. Rheumatology. 2000;39(7):707–713. https://doi.org/10.1093/rheumatology/39.7.707.
13. Hoffmann A. L., Milman N., Byg K. E. Childhood sarcoidosis in Denmark 1979-1994: incidence, clinical features and laboratory results at presentation in 48 children. Acta paediatrica. 2004;93(1):30–36. https://doi.org/10.1080/08035250310007213.
14. Salukhov V. V., Kovalevskaya E. A. Glucocorticoid-induced osteoporosis: current state of the problem. Medline. Clinical medicine. Therapy. 2018;19:832–60. (In Russ.).
15. Rizzato G., Montemurro L., Fraioli P. Bone mineral contentin sarcoidosis. Semin. Respir. Med. 1992;13:411–23.
16. Salukhov V. V., Kovalevskaya E. A., Kurbanova V. V. Bone and extraosseous effects of vitamin D, as well as the possibilities of drug correction of its deficiency. Medical Council. 2018; 4:86–89. https:// doi.org/10.21518/2079-701X-2018-4-90-99. (In Russ.).
17. Obesity and associated diseases: conservative and surgical treatment. Manual for doctors / eds by S. F. Bagnenko, E. V. Kryukov. St. Petersburg. Special literature. 2022. 4778 p. (In Russ.).
18. Salukhov V. V., Kovalevskaya E. A. The relationship between obesity, vitamin D deficiency and osteoporosis, as well as methods of their correction. Pharmateka. 2023;1–2:232–239. https://dx.doi.org/10.18565/pharmateca.2023.1-2.232-239. (In Russ.).
19. Maksimov M. L., Zvegintseva A. A., Ismailova M. A., Kulagina L. Yu. Use of vitamin D in the prevention of infection and development of severe forms of the new coronavirus infection COVID-19. Practical Medicine. 2021;19(4):37–44. https://doi.org/10.32000/2072-1757-2021-4-37-44. (In Russ.).
20. Baughman R. P., Papanikolaou I. Current concepts regarding calcium metabolism and bone health in sarcoidosis. Curr. Opin. Pulm. Med. 2017;23:000–000. https://doi.org/10.1097/MCP.0000000000000400.
21. Zhou Y., Lower E. E. Balancing altered calcium metabolism with bone health in sarcoidosis. Semin Respir Crit Care Med. 2020;41:618–625. https://doi.org/10.1055/s-0040-1713009.
22. Hamada K., Nagai S., Tsutsumi T., Izumi T. Ionized calcium and 1,25-dihydroxyvitamin D concentration in serum of patients with sarcoidosis. Eur Respir J. 1998;11:1015–1020.
23. Kavathia D., Buckley J. D., Rao D. et al. Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis. Respir Med. 2010;104:564–570. https://doi.org/10.1016/j.rmed.2009.12.004.
24. Vucinic V., Skodric-Trifunovic V., Ignjatovic S. How to diagnose and manage difÏcult problems of calcium metabolism in sarcoidosis: an evidence-based review. Current Opinion in Pulmonary Medicine. 2011;17:297–302. https://doi.org/10.1097/MCP.0b013e328348b3cb. 25. Newman L. S., Rose C. S., Maier L. A. Sarcoidosis. N. Engl. J. Med. 1997;336:1224–1235.
25. Capolongo G., Xu L. H. R., Accardo M. et al. Vitamin-D status and mineral metabolism in two ethnic populations with sarcoidosis. J Investig Med. 2016;64(5):1025–34. https://doi.org/10.1136/jim-2016-000101.
26. Mittal S., Pogorzelski K., Huxel C. et al. An Atypical Case of Extrapulmonary Sarcoidosis with Severe Hypercalcemia as Initial Presentation, Successfully Treated with Glucocorticoids. Clin. Pract. 2024;14:1264–1269. https://doi.org/10.3390/clinpract14040102.
27. Sharma O):Renal sarcoidosis and hypercalcaemia. Eur Respir Monograph. 2005;(10):220–232.
28. Duzen O., Erkoc R., Begenik H. et al. The Course of Hypercalciuria and Related Markers of Bone Metabolism Parameters Associated with Corticosteroid Treatment. Renal Failure. 2012;34(3):338–342. https:// doi.org/10.3109/0886022X.2011.648596.
29. Sodhi A., Aldrich T. Vitamin D Supplementation: Not So Simple in Sarcoidosis. Am. J. Med. Sci. 2016;352:252–257. https://doi.org/10.1016/j.amjms.2016.05.027.
30. Kamphuis L. S., Bonte-Mineur F., van Laar J. A. et al. Calcium and vitamin D in sarcoidosis):Issupplementation safe? J. Bone Miner. Res. 2014;29:2498–2503. https://doi.org/10.1002/jbmr.2262.
31. Glass A. R., Eil C. Ketoconazole induced reduction in serum dihydroxyvitamin D and total serum calcium in hypercalcemic patients. J. Clin Endocrinol Metab. 1988;66:934–8.
32. Vizel A. A., Vizel I. Yu. Sarcoidosis: international consensus documents and recommendations. RMJ. 2014;(5):356–360. (In Russ.).
33. Saidenberg-Kermanac’h N., Semerano L., Nunes H. et al. Bone fragility in sarcoidosis and relationships with calcium metabolism disorders: a cross sectional study on 142 patients. Arthritis Res Ther. 2014;16(02):R78. https://doi.org/10.1186/ar4519.
34. Tatsuno I., Suzuki S., Yoshida T. et al. Disease-related risk of vertebral fracture during glucocorticoid treatment of collagen vascular diseases. J Rheumatol. 2011;38:2270–2272. https://doi.org/10.2169/internalmedicine.50.4443.
35. Montemurro L., Fraioli P., Rizzato G. Bone loss in untreated longstanding sarcoidosis. Sarcoidosis. 1991;8(01):29–34.
36. Lobanova K. G., Ushanova F. O. Diagnostics and treatment of osteoporosis: a paradigm shift. FOCUS Endocrinology. 2024;1(5):65–73. https://doi.org/10.62751/2713-0177-2024-5-1-09. (In Russ.).
Review
For citations:
Salukhov V.V., Kovalevskaya E.A., Burkova J.S. Current concepts of hypercalcemia in sarcoidosis. New St. Petersburg Medical Records. 2025;(1):44-53. (In Russ.) https://doi.org/10.24884/1609-2201-2025-104-1-44-53
Views:
21
Email this article 